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OBJECTIVES The purpose of this research was to determine the relative safety and efficacy of multiple (2)
overlapping Cypher sirolimus-eluting stents (SES) (Johnson & Johnson, New Brunswick,
New Jersey).
BACKGROUND Overlapping coronary stents are common. The periprocedural and late clinical and angio-
graphic consequences of overlapped coronary stents are not clearly defined, particularly for
drug-eluting stents.
METHODS All patients enrolled into five clinical trials of the SES were analyzed. Three of these trials
were prospective randomized comparisons of the SES to the bare-metal stent (BMS),
and two were prospective non-randomized trials of SES-treated patients with histori-
cal controls. All clinical and angiographic outcomes in overlap-stent–treated patients
were compared by stent type and with single-stent–treated patients for the same stent
device.
RESULTS In all, 575 patients with stent overlap (337 SES, 238 BMS) and 1,162 patients with single
stents (697 SES, 465 BMS) were analyzed. Stent overlap was associated with a greater late
lumen loss in stent and more frequent angiographic restenosis regardless of stent type. Among
overlap-stent–treated patients, the SES provided similar magnitude of restenosis benefit as
observed for single-stent–treated patients. Overlapped SES was not associated with an
increase in myocardial infarction.
CONCLUSIONS The strategy of SES overlap, when required, is both safe and efficacious in reducing restenosis
with no increase in the incidence of myocardial infarction or major adverse cardiovascular
events, when compared with a bare metal coronary stent prosthesis. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.0582006;48:21–31) © 2006 by the American College of Cardiology Foundation
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fhe implantation of multiple (2) overlapping coronary
tents may be prompted by excessive target lesion length,
ncomplete lesion coverage, and/or endoluminal injury
equiring additional stent scaffolding beyond the margins
f the initial stent deployed. Furthermore, multiple
verlapping stents may be required to repair extensive or
piral coronary dissection. Stent strut overlap has been
ncriminated both as a stimulus to neointimal hyperplasia
nd as a correlate to late angiographic restenosis in man
1– 4). However, the relative contribution(s) of target
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006, accepted February 17, 2006.esion length, total stented segment length, and number
f stents deployed per target lesion (stent overlap) toward
he occurrence of periprocedural major adverse cardio-
ascular events (MACE) and/or late angiographic reste-
osis have been the subject of debate (5–10). Specifically,
he role of stent overlap as an independent determinant of
estenosis is unclear. Recently, concern has been raised by
he observation of an increased incidence of periproce-
ural myocardial infarction after overlap of the paclitaxel-
luting TAXUS stent (Boston Scientific, Marlborough,
assachusetts) (11–13). As the currently available drug-
luting stent platforms differ considerably in metal plat-
orm design, polymer and active pharmacologic agent,
he extent to which the observations made after TAXUS
tent overlap may be extrapolated to the Cypher
irolimus-eluting stent (SES) (Johnson & Johnson, New
runswick, New Jersey) is unknown. The purpose of the
resent study was to determine if the deployment of
ultiple, overlapping SES is associated with an excess of
ajor adverse clinical events (especially myocardial in-
arction) and/or angiographic restenosis when compared
ith bare-metal stent (BMS) treatment.
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ll patients enrolled into five clinical trials of the SES who
eceived multiple overlapped stents or single stent were
nalyzed (14–19). The individual trials as well as the
umbers of patients treated with single versus multiple
verlapped SES or bare metal (control) stents are shown in
able 1. All trials specified single target vessel treatment
nd allowed for the use of more than one stent per target
esion. Stents of 2.5 mm, 3.0 mm, and 3.5 mm diameter as
ell as 8.0 and 18.0 mm length were available for each trial.
ll trials had pre-specified clinical and angiographic
ollow-up as well as similar pre-specified analyses of serial
ardiac enzymes and electrocardiograms. Cardiac enzymes
creatine kinase [CK] and CK-MB) were obtained 6 to 8 h,
2 to 16 h, and 18 to 24 h after the procedure or before
ospital discharge. The 12-lead electrocardiogram (ECG)
as obtained before and within 24 h after the procedure or
t the time of hospital discharge (whichever came first). The
iagnosis of Q-wave myocardial infarction was defined as
he development of new, pathological Q waves in two or
ore continuous leads (as assessed by the ECG core
aboratory) with post-procedure CK or CK-MB levels
levated above normal. The diagnosis of non–Q-wave
yocardial infarction required elevation of post-procedure
K levels to greater than two times normal with elevated
K-MB in the absence of new pathological Q waves. All
ACE were adjudicated by independent clinical events
Abbreviations and Acronyms
BMS  bare-metal stent
CK  creatine kinase
MACE  major adverse cardiovascular events
PES  paclitaxel-eluting stent
QCA  quantitative coronary angiography
SES  sirolimus-eluting stent
SIRIUS  Sirolimus-Eluting Stent in Coronary
Lesions trial
able 1. Individual Trials As Well As the Numbers of Patients
reated With Single Versus Multiple Overlapped SES or BMS
Control)
Study
# Clinical
Sites
SES BMS Control
Overlap
All
(% Overlap) Overlap
All
(% Overlap)
IRIUS 53 173 533 (32.5) 167 525 (31.8)
-SIRIUS 35 61 175 (34.9) 55 177 (31.1)
-SIRIUS 8 18 50 (36.0) 16 50 (32.0)
IRECT 16 70 225 (31.1) — —
VELTE 10 15 101 (14.9) — —
OOLED 337 1,084 (31.1) 238 752 (31.6)
MS  bare-metal stent; C-SIRIUS  Canadian Study of the Sirolimus-Eluting
tent in the Treatment of Patients with Long De Novo Lesions in Small Native
oronary Arteries; DIRECT  Direct Stenting Using the Sirolimus-Eluting Stent
rial; E-SIRIUS  Sirolimus-Eluting Stents for Treatment of Patients with Long
therosclerotic Lesions in Small Coronary Arteries; SES  sirolimus-eluting stent;
IRIUS  Sirolimus-Eluting Stents in Coronary Lesions trial; SVELTE  Aw
ulticenter, non-randomized, historical controlled study in patients with de novo
ative coronary artery lesions in Small VessELs treated with the Cypher sTEnt.ommittees. Three of the trials (SIRIUS [Sirolimus-Eluting
tent in Coronary Lesions], E-SIRIUS [Sirolimus-Eluting
tents for Treatment of Patients With Long Atheroscle-
otic Lesions in Small Coronary Arteries], C-SIRIUS
Canadian Study of the Sirolimus-Eluting Stent in the
reatment of Patients with Long De Novo Lesions in Small
ative Coronary Arteries]) were prospective, randomized
ontrolled comparisons of the SES to the bare metal Bx
elocity stent (BMS) (Cordis/J&J, Miami Lakes, Florida),
nd two (DIRECT [Direct Stenting Using the Sirolimus-
luting Stent], SVELTE [A multicenter, non-randomized,
istorical controlled study in patients with de novo native
oronary artery lesions in Small VessELs treated with the
ypher sTEnt]) were prospective non-randomized trials of
ES-treated patients with historical controls. These non-
andomized trials were performed with rigorous protocol
dherence, clinical event committee adjudication of all
ACE as well as data and safety monitoring boards. The
on-randomized historical control groups from these
rials were not included in this analysis. To avoid bias
aused by using non-randomized trial data, additional
nalyses were performed including examination of patient
aseline clinical and angiographic characteristics as well
s study impact on all major end points for patients
nrolled in all five trials with a similar analysis of those
atients enrolled into the three randomized trials. The
esults of these additional analyses (data not shown)
emonstrate that patient baseline characteristics were
imilar for all five trials and that study was not a
ignificant confounder for any major end point. A sepa-
ate analysis confined to the three randomized trials
rovides results that are similar to the pooled five trial
nalysis with no change in any conclusion drawn (Ap-
endix). In all trials, the overlapping stent subgroup was
etermined by both clinical site as well as independent
uantitative coronary angiographic (QCA) core lab anal-
sis. Standard QCA definitions for “in-stent” (within the
tented segment only) and “in-lesion” (stented segment
lus 5 mm proximal and distal margins) were employed
or measurements of late lumen loss and binary angio-
raphic restenosis. Patients who were treated with mul-
iple, non-overlapping stents in the same target vessel
ere not included in the present analysis.
tatistical methods. Summaries of mean and SD for each
reatment group are reported. For analysis of continuous
ariables, a two sample t test was conducted for comparison
f treatment difference, and both t test p value as well as
5% confidence intervals of the mean difference are re-
orted. The homogeneity of the variance was tested. For
ategorical variables, Cochran-Mantel-Haenszel statis-
ics were employed, and the mean difference as well as
5% confidence intervals and Fisher exact test p values
re reported. A univariate and multivariable predictor
nalysis using logistic regression in-stent binary resteno-
is was performed. The predictors were chosen by step-
ise procedure criteria using an entry criterion of 0.20
Table 2. Baseline Clinical and Angiographic Demographics by Stent Type and Stent Overlap Status
Variables
BMS SES
p Values
Overlap Stent (1)
n  238 Patients
Single Stent (2)
n  465 Patients
Overlap Stent (3)
n  337 Patients
Single Stent (4)
n  697 Patients (1) vs. (2) (3) vs. (4) (1) vs. (3) (2) vs. (4)
Age (yrs) 61.94  10.270 62.31  10.856 62.15  11.327 61.84  11.197 0.66 0.67 0.81 0.48
Diabetes mellitus 27.8% 28.4% 26.1% 25.5% 0.93 0.88 0.70 0.28
Prior MI 37.8% 34.8% 34.2% 31.1% 0.45 0.35 0.42 0.20
Prior PTCA 20.2% 22.2% 25.6% 26.5% 0.56 0.76 0.13 0.10
Prior CABG 10.5% 6.2% 11.6% 7.5% 0.05 0.03 0.79 0.48
Hyperlipidemia 77.4% 72.2% 76.4% 74.6% 0.14 0.54 0.84 0.37
Hypertension 58.0% 69.4% 66.7% 65.5% 0.01 0.73 0.04 0.18
Current smoker 30.2% 20.2% 24.3% 22.2% 0.01 0.47 0.15 0.42
Congestive heart failure 5.2% 6.7% 5.7% 4.9% 0.51 0.65 0.85 0.24
Unstable angina, Braunwald classification II/III 53.0% 49.6% 54.6% 50.4% 0.59 0.41 0.81 0.93
Ejection fraction (%) 57.10  10.932 57.27  10.849 56.57  11.711 56.90  10.759 0.84 0.66 0.59 0.57
Diseased native coronary arteries 50% stenosis
Single 58.0% 61.6% 52.7% 62.6% 0.37 0.01 0.23 0.76
Double 27.7% 27.4% 28.3% 24.6% 0.93 0.22 0.93 0.30
Triple 14.3% 11.0% 19.0% 12.8% 0.22 0.01 0.14 0.41
Vessel location
LAD 43.8% 47.2% 45.1% 46.8% 0.43 0.64 0.80 0.90
LCX 24.2% 23.9% 24.5% 27.0% 1.00 0.41 1.00 0.24
RCA 31.3% 28.4% 30.1% 25.6% 0.49 0.13 0.78 0.28
LMCA 0.8% 0.2% 0.0% 0.6% 0.27 0.31 0.18 0.40
SVG 0.0% 0.2% 0.3% 0.0% 1.00 0.34 1.00 0.43
Eccentric 31.4% 34.5% 33.4% 42.1% 0.45 0.01 0.65 0.01
Tortuosity, mod–severe 8.8% 3.9% 4.2% 6.8% 0.01 0.12 0.03 0.04
Calcification, mod–severe 19.2% 14.9% 19.4% 16.1% 0.16 0.22 1.00 0.62
Modified ACC/AHA lesion class
A 3.8% 9.3% 4.5% 13.2% 0.01 0.01 0.83 0.04
B1 24.7% 43.3% 22.7% 35.5% 0.01 0.01 0.62 0.01
B2 32.6% 36.9% 29.3% 38.6% 0.28 0.01 0.41 0.58
C 38.9% 10.6% 43.6% 12.6% 0.01 0.01 0.27 0.31
ACC  American College of Cardiology; AHA  American Heart Association; BMS  bare-metal stent; CABG  coronary artery bypass grafting; LAD  left anterior descending coronary artery; LCX  left circumflex artery; LMCA  left
main coronary artery; MI  myocardial infarction; mod  moderate; PTCA  percutaneous transluminal coronary angioplasty; RCA  right coronary artery; SES  sirolimus-eluting stent; SVG  saphenous vein graft.
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Table 3. Baseline Pre-Procedural Quantitative Coronary Angiographic and Procedural Variables by Stent Type and Stent Overlap Status
Variables
BMS SES
p Values
Overlap Stent (1)
n  238 Patients
Single Stent (2)
n  465 Patients
Overlap Stent (3)
n  337 Patients
Single Stent (4)
n  697 Patients (1) vs. (2) (3) vs. (4) (1) vs. (3) (2) vs. (4)
Pre-procedure QCA
Reference vessel diameter (mm) 2.73  0.445 2.73  0.475 2.74  0.438 2.69  0.443 1.00 0.09 0.90 0.14
MLD (mm) 0.91  0.345 0.95  0.374 0.93  0.372 0.96  0.390 0.13 0.30 0.51 0.92
Percent diameter stenosis 66.79  10.736 64.99  12.113 66.20  11.772 64.59  12.474 0.04 0.05 0.53 0.59
Lesion length (mm) 18.15  7.165 12.31  3.620 17.98  6.849 12.01  4.002 0.01 0.01 0.78 0.19
GP IIb/IIIa inhibitor therapy 53.4% 47.5% 52.8% 47.9% 0.15 0.14 0.93 0.90
Procedure success 96.6% 99.6% 97.9% 98.6% 0.01 0.44 0.43 0.14
Lesion success 100.0% 100.0% 100.0% 100.0% — — — —
Device success 99.6% 99.1% 98.5% 99.9% 0.67 0.02 0.41 0.09
Stent balloon dilatation—pressure (atm) 14.87  2.593 13.60  2.600 15.00  2.854 14.08  2.835 0.01 0.01 0.59 0.01
Post-stent nominal balloon diameter/artery ratio 1.00  0.149 0.96  0.145 1.01  0.434 0.98  0.155 0.01 0.21 0.76 0.07
Post-procedure non-dissection 99.2% 99.6% 98.8% 99.1% 0.61 0.74 1.00 0.49
Diameter of stent implanted
2.5 mm 24.1% 23.1% 24.8% 23.9% 0.71 0.71 0.84 0.78
3.0 mm 50.6% 48.7% 47.8% 41.9% 0.56 0.03 0.35 0.02
3.5 mm 25.3% 28.2% 24.9% 27.1% 0.31 0.36 0.89 0.69
Length of stents implanted
8 mm 34.4% 0.9% 33.5% 1.4% 0.01 0.01 0.76 0.57
18 mm 65.6% 99.1% 66.5% 98.6% 0.01 0.01 0.76 0.57
Final stents length (mm) by QCA 27.54  7.856 17.90  1.115 28.22  7.206 18.35  2.635 0.01 0.01 0.32 0.01
Total stent length implanted (mm)—CRF 31.46  8.420 17.91  0.924 32.27  8.449 18.44  2.763 0.01 0.01 0.26 0.01
Total stent length/lesion length ratio (QCA) 1.70  0.701 1.59  0.576 1.84  0.909 1.70  0.781 0.06 0.01 0.03 0.01
CRF  case report form; GP  glycoprotein; MLD  minimum lumen diameter; QCA  quantitative coronary angiography; other abbreviations as in Table 2.
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Table 4. Post-Procedure and Late (8-Month) Quantitative Coronary Angiography by Stent Type and Stent Overlap Status
Variables
BMS SES
p Values
Overlap Stent (1)
n  238 Patients
Single Stent (2)
n  465 Patients
Overlap Stent (3)
n  337 Patients
Single Stent (4)
n  697 Patients (1) vs. (2) (3) vs. (4) (1) vs. (3) (2) vs. (4)
Post-procedure
In-lesion
MLD (mm) 2.29  0.415 2.34  0.472 2.30  0.439 2.29  0.463 0.18 0.77 0.83 0.09
Percent diameter stenosis 18.10  8.097 15.94  8.765 17.57  9.007 16.76  9.634 0.01 0.20 0.46 0.13
In-stent
MLD (mm) 2.57  0.373 2.63  0.430 2.56  0.401 2.60  0.413 0.06 0.13 0.71 0.21
Percent diameter stenosis 7.70  8.369 5.00  8.160 7.98  8.237 5.13  8.376 0.01 0.01 0.69 0.80
8-month follow-up
In-lesion
MLD (mm) 1.33  0.710 1.60  0.686 2.06  0.581 2.07  0.534 0.01 0.96 0.01 0.01
Percent diameter stenosis 51.43  23.174 41.60  22.012 24.77  15.979 23.34  14.321 0.01 0.22 0.01 0.01
In-stent
MLD (mm) 1.36  0.738 1.69  0.758 2.30  0.586 2.44  0.537 0.01 0.01 0.01 0.01
Percent diameter stenosis 50.57  24.193 38.06  24.841 15.82  17.550 8.89  14.604 0.01 0.01 0.01 0.01
Binary restenosis
In-lesion 50.6% 33.0% 8.9% 5.8% 0.01 0.13 0.01 0.01
In-stent 50.6% 31.6% 6.2% 1.7% 0.01 0.01 0.01 0.01
Marginal 14.3% 10.4% 3.5% 5.0% 0.20 0.37 0.01 0.01
Proximal edge 7.1% 6.9% 2.4% 4.1% 1.00 0.30 0.03 0.08
Distal edge 12.1% 6.0% 1.5% 1.3% 0.02 0.76 0.01 0.01
Acute gain (mm)
In-lesion 1.38  0.424 1.38  0.481 1.37  0.426 1.34  0.462 0.95 0.23 0.76 0.08
In-stent 1.66  0.409 1.68  0.444 1.63  0.410 1.64  0.429 0.63 0.65 0.39 0.21
Late loss (mm)
In-lesion 0.94  0.636 0.75  0.655 0.23  0.477 0.21  0.411 0.01 0.58 0.01 0.01
In-stent 1.19  0.655 0.95  0.678 0.24  0.477 0.14  0.397 0.01 0.01 0.01 0.01
Within the proximal edge 0.42  0.698 0.28  0.561 0.13  0.447 0.17  0.440 0.03 0.25 0.01 0.01
Within the distal edge 0.33  0.647 0.24  0.577 0.06  0.419 0.10  0.396 0.09 0.21 0.01 0.01
MLD  minimum lumen diameter; other abbreviations as in Table 2.
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Sirolimus-Eluting Stent Overlap July 4, 2006:21–31ith a stay criterion of 0.10 in the multiple logistic
egression model.
All statistical analyses were performed using SAS Version
.2 (SAS Institute, Cary, North Carolina). In the multiple
omparisons of QCA and clinical end points among the
ubgroups by treatment and overlap stent or single stent use,
onferroni adjusted significance level of 0.0125 (0.05/4)
ere applied. For any other comparisons, a statistical
ignificance level of 0.05 was used.
ESULTS
aseline clinical and angiographic demographic variables for
atients treated with either single or overlapped SES as well
s BMS controls are shown in Table 2. The only significant
linical difference observed between stent overlap patient
ohorts was a higher incidence of systemic hypertension in
ES treated patients. The only significant clinical difference
bserved between single-stent–treated patient cohorts was a
ore frequent history of smoking in SES-treated patients.
ll other clinical variables were similar between single
ersus overlap or SES versus BMS-treated patient groups.
aseline quantitative coronary angiographic and procedural
ariables are shown in Table 3. Baseline angiography was
imilar in overlap-stent–treated patient cohorts except for more
requent moderate or severe vessel tortuosity in BMS-treated
atients. Procedural variables were similar for overlap stent-
reated patients except for a greater total stent-length-to-
esion-length ratio determined by QCA in SES-treated pa-
ients. The length of overlapped stent segment (mean SD)
y QCA was assessed only in the SIRIUS trial and was
.6  9.1 mm for SES, 4.0  4.9 mm for BMS. Quanti-
ative coronary angiographic variables post-procedure and atigure 1. Late lumen loss by quantitative coronary angiography stratified by sten
tent; SES  sirolimus-eluting stent.-month follow-up are shown in Table 4. Stent overlap
vs. single-stent deployment) was associated with a signifi-
ant increase in both in-stent and in-lesion binary angio-
raphic restenosis for patients treated with BMS (p 
.001). Conversely, SES overlap (vs. single SES) was not
ssociated with a significant difference in in-lesion resteno-
is (8.9 vs. 5.8%, respectively; p  0.1314), although
n-stent restenosis was increased (6.2 vs. 1.7%, respectively;
 0.0016). Similarly, although late lumen loss in-stent
as increased by stent overlap regardless of stent type (SES
r BMS), in-lesion late lumen loss did not differ signifi-
antly between overlap and single SES-treated patients.
ate lumen loss in-stent, as well as in the proximal and
istal stent margin segments, is illustrated by stent type and
verlap status in Figure 1. After multivariable analysis with
djustments for lesion length and implanted total stent
ength, no differences in late lumen loss in-stent were
bserved for either SES- or BMS-treated patients stratified
y overlap status.
Major adverse cardiovascular events to 30 days and 1 year
fter stent deployment by stent type and overlap status are
hown in Table 5. At 1 year, a significant increase in
ACE and target lesion revascularization (p  0.001) was
bserved for overlapped BMS but not SES stents. Further-
ore, among overlap stent-treated patients, no difference in
otal myocardial infarctions (both Q-wave and non–Q-
ave) to either 30 days or 1 year (Figs. 2A to 2C) was
bserved by stent type or total implanted stent length.
lthough both late target vessel revascularization and target
essel failure were increased in stent-overlap–treated patients
egardless of stent type, SES overlap was less frequently
ssociated with these adverse events than was BMS overlapt type, overlapped stent status, and region of interest. BMS  bare-metal
Table 5. Periprocedural and Late (1-Year) Clinical Events by Stent Type and Stent Overlap Status
Variables
BMS SES
p Values
Overlap Stent (1)
n  238 Patients
Single Stent (2)
n  465 Patients
Overlap Stent (3)
n  337 Patients
Single Stent (4)
n  697 Patients (1) vs. (2) (3) vs. (4) (1) vs. (3) (2) vs. (4)
Events to 30 days
MACE 3.8% 0.9% 2.4% 1.6% 0.01 0.46 0.33 0.43
Death 0.4% 0.0% 0.3% 0.0% 0.34 0.33 1.00 —
Cardiac death 0.4% 0.0% 0.3% 0.0% 0.34 0.33 1.00 —
Non-cardiac death 0.0% 0.0% 0.0% 0.0% — — — —
Myocardial infarction (Q- or non–Q-wave) 3.4% 0.9% 2.1% 1.6% 0.03 0.61 0.43 0.43
Q-wave 0.0% 0.0% 0.9% 0.1% — 0.10 0.27 1.00
Non–Q-wave 3.4% 0.9% 1.2% 1.4% 0.03 1.00 0.08 0.43
Emergent CABG 0.0% 0.0% 0.0% 0.0% — — — —
Target lesion revascularization 0.0% 0.0% 0.6% 0.1% — 0.25 0.51 1.00
CABG 0.0% 0.0% 0.0% 0.0% — — — —
PTCA 0.0% 0.0% 0.6% 0.1% — 0.25 0.51 1.00
Events to 360 days
MACE 31.5% 18.1% 7.4% 6.7% 0.01 0.70 0.01 0.01
Death 1.3% 0.4% 0.9% 1.6% 0.34 0.57 0.70 0.09
Cardiac death 0.8% 0.2% 0.6% 0.7% 0.27 1.00 1.00 0.41
Non-cardiac death 0.4% 0.2% 0.3% 0.9% 1.00 0.44 1.00 0.25
Myocardial infarction (Q- or non–Q-wave) 4.6% 2.2% 2.7% 2.6% 0.10 1.00 0.25 0.70
Q-wave 0.0% 0.2% 1.2% 0.4% 1.00 0.22 0.15 0.65
Non–Q-wave 4.6% 1.9% 1.5% 2.2% 0.05 0.63 0.04 0.84
Emergent CABG 0.0% 0.0% 0.0% 0.0% — — — —
Target lesion revascularization 28.2% 16.8% 4.7% 3.3% 0.01 0.30 0.01 0.01
CABG 2.1% 1.3% 0.0% 0.6% 0.52 0.31 0.01 0.21
PTCA 27.3% 16.1% 4.7% 3.0% 0.01 0.21 0.01 0.01
Target vessel failure 32.8% 20.6% 11.6% 7.2% 0.01 0.02 0.01 0.01
Target vessel revascularization 29.4% 19.8% 9.5% 5.0% 0.01 0.01 0.01 0.01
Stent thrombosis 0.4% 0.0% 0.3% 0.3% 0.34 1.00 1.00 0.52
Acute 0.0% 0.0% 0.0% 0.1% — 1.00 — 1.00
Subacute 0.4% 0.0% 0.3% 0.1% 0.34 0.55 1.00 1.00
Late thrombosis 0.4% 0.4% 0.0% 0.1% 1.00 1.00 0.41 0.57
CABG  coronary artery bypass grafting; MACE  major adverse cardiac event is a composite end point comprised of death, any myocardial infarction (Q-wave or World Health Organization-defined non–Q-wave) to 30 days
post-procedure and target-vessel-related myocardial infarction (Q-wave or World Health Organization-defined non–Q-wave) after 30 days, or target lesion revascularization; PTCA percutaneous transluminal coronary angioplasty; other
abbreviations as in Table 2.
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Sirolimus-Eluting Stent Overlap July 4, 2006:21–31Fig. 3). Further analysis of late binary angiographic and
linical restenosis (Fig. 4) by stent type and overlap (vs.
ingle stent) status demonstrates a significant benefit for
estenosis reduction in favor of the SES.
Both univariate and multivariate predictors of in-stent
inary angiographic restenosis were analyzed. After adjust-
ent for covariates of total stent length implanted and
arget lesion length, stent overlap (vs. single stent) was a
ignificant predictor of in-stent restenosis only for BMS
but not SES) treated patients (Table 6).
ISCUSSION
he scenario of stent overlap necessitated by excessive target
esion length, incomplete target lesion coverage, or stent
arginal dissection may complicate up to one-third or more
f coronary stent procedures (15–19). The relative impor-
ance of stent metal overlap as a stimulus for neointimal
igure 2. (A) Total myocardial infarction (MI) (both Q- and non–Q-
ave) by stent type (bare-metal stents [BMS], n  238; sirolimus-eluting
tent [SES], n  337) in patients treated with overlapping stents.
B) Incidence of total MI at 30 days by stent type stratified by total
mplanted stent length. (C) Total MI at 360 days by stent type stratified by
otal implanted stent length. Solid bars  BMS; open bars  SES.roliferation versus the efficacy of stent-based drug elution
b
so suppress neointimal growth has not been adequately
efined (20). Furthermore, as the potential for both early
eriprocedural and late toxicity related to overlapped drug-
luting stents may be derived from the specific metal
latform, polymer, or pharmacologic agent utilized, it is
mportant to carefully analyze all clinical and angiographic
utcomes in these patients for each available device. This
tudy provides novel insights into coronary stent overlap for
oth BMS and SES. The major observations derived from
his study include: 1) BMS overlap is associated with an
ncreased incidence of myocardial infarction and total
ACE that was not apparent for SES overlap; 2) both
MS and SES overlap are associated with a greater degree
f late lumen loss, as well as more frequent angiographic
n-stent binary restenosis; 3) clinical restenosis (target lesion
evascularization) was increased by stent overlap for BMS
ut not SES-overlap–treated patients; and 4) among stent-
verlap–treated patients, SES was associated with a marked
eduction in the frequency of both angiographic and clinical
estenosis with no difference in the occurrence of peripro-
edural or late myocardial infarction when compared with
MS-treated patients. Thus, stent overlap is associated with
eointimal proliferation and subsequent late lumen loss
egardless of stent type. Although both angiographic and
linical restenosis are increased after stent overlap regardless
f stent type, polymer-based stent elution of sirolimus
s effective in reducing the frequency of restenosis and
rovides the same magnitude of restenosis benefit in overlap
s observed for single-stent–treated patients.
afety of overlapping stents. Recent reports have raised
oncerns regarding safety after the practice of stent overlap
ith currently available drug-eluting stents. Indeed, the
umulative effect of “double-dose” metal, polymer, and drug
as specifically discouraged by protocol in the pivotal
AXUS-IV trial of the TAXUS paclitaxel-eluting stent
PES) (Boston Scientific). In the TAXUS-V (12,13) and
VI (14) trials, which compared the PES in a randomized
ashion with the bare metal EXPRESS stent (Boston
cientific) platform for the treatment of patients with longer
arget lesion lengths, stent overlap was required in an
igure 3. Target lesion revascularization (TLR) and target vessel revascu-
arization (TVR) through 360 days as well as target vessel failure (TVF)
composite occurrence of death, myocardial infarction, and TLR) stratified
y stent type in patients treated with overlapping stents. BMS bare metal
tent; SES  sirolimus-eluting stent.
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July 4, 2006:21–31 Sirolimus-Eluting Stent Overlapppreciable portion of subjects. Recent analyses from these
rials have reported an increased incidence of periprocedural
yocardial enzyme elevation in patients treated with PES
verlap when compared with those who received overlap-
ing EXPRESS stents. A post-hoc exploratory angio-
raphic analysis has suggested that a reduction in side
ranch flow in PES overlap stent-treated patients may
xplain these observed differences in periprocedural infarc-
ion (21). As the metal platforms are similar between the
ES and EXPRESS stent prostheses, any observed differ-
nce in the occurrence of myocardial infarction not attrib-
table to chance variability alone must relate to the specific
olymer and/or pharmacologic agent disposed on the PES.
urthermore, the issue of whether or not an increased
ncidence of periprocedural infarction also complicates over-
ap of non-PES polymer-based drug-eluting stents has not
een defined. In this regard, the fact that no increase in the
ncidence of myocardial infarction at either 30 days or 1 year
as observed in the present study of patients treated with
verlapped SES is in contrast with the results of the
AXUS-V and -VI trials. If periprocedural infarction
elated to stent overlap is associated only with PES (but not
igure 4. In-stent binary (50%) angiographic restenosis (A) and target l
tatus. *p  0.0001 for comparisons sirolimus-eluting stent (SES) versus ba
verlap versus single stent. ‡p  0.0001 for comparisons SES versus BMS;
tent. Solid bars  BMS; open bars  SES.
able 6. Predictors of In-Stent Binary Stenosis by Multiple Logi
Variables Coefficie
ES
Total implanted stent length 0.088
Prior MI 0.901
History of diabetes 0.821
MS
Treatment group (overlap vs. single) 0.779
History of diabetes 0.717
Post-procedure in-stent minimal lumen diameter (mm) 0.620
Pre-procedure minimal lumen diameter (mm) 0.479
Vessel location—LAD 0.222ultivariate predictors were chosen by stepwise procedure using an entry criterion of 0.20
BMS  bare-metal stent; CI  confidence interval; LAD  left anterior descending cES) when directly compared with their respective BMS
ounterparts, differences in polymer thickness or viscoelastic
roperties, as well as pharmacologic agent must be explored.
oth coating weight and thickness differ between the PES
ranslute (Boston Scientific) (1,227 and 18 m, respec-
ively) and the SES EVA-BMA (SurModics, Minneapolis,
innesota) (600 and 10 m, respectively) polymers
22,23). For example, Translute demonstrates polymer
webbing” on in-vitro PES deployment (24), a phenomenon
ot observed with the EVA-BMA polymer-coated SES.
lthough differences in endoluminal histology have been
eported between overlapped PES and SES in a porcine
odel (24,25), what specific effects are attributable to
olymer versus pharmacologic agent (paclitaxel vs. siroli-
us) (26) and the proposed mechanisms by which these
istologic differences may be temporally related to infarction
emain unclear. Finally, although data are limited, neither
ES nor SES overlap appear to be associated with late
ngiographic stent malapposition or aneurysm formation by
ither QCA or intravascular ultrasound (12,13,27,28).
tent overlap and neointimal proliferation. An impor-
ant observation of this study is the association between
revascularization (B) stratified by stent type and overlap (vs. single) stent
tal stent (BMS) and BMS overlap versus single stent; p  0.0016 for SES
.0006 BMS overlap versus single stent; p  NS SES overlap versus single
egression
Standard Error Odds Ratio (95% CI) p Value
0.0175 1.902 (1.05–1.13) 0.01
0.4265 2.462 (1.07–5.68) 0.03
0.4327 2.275 (0.97–5.31) 0.06
0.1996 2.180 (1.47–3.22) 0.01
0.2073 2.050 (1.36–3.08) 0.01
0.2699 0.538 (0.32–0.91) 0.02
0.2958 0.619 (0.35–1.11) 0.10
0.1945 1.249 (0.85–1.83) 0.25esion
re-mestic R
nt
0
0
9
4
7
5
6
1with a stay criterion of 0.10.
oronary artery; MI  myocardial infarction; SES  sirolimus-eluting stent.
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Sirolimus-Eluting Stent Overlap July 4, 2006:21–31tent overlap and neointimal proliferation for both SES and
MS. For both stent platforms, late quantitative coronary
ngiographic measurements in-stent demonstrate that min-
mum lumen diameter was significantly less, while percent
iameter stenosis, late lumen loss, and binary angiographic
estenosis were significantly greater in overlapped versus
ingle stents. Nevertheless, the relative magnitude of reste-
osis reduction observed in patients treated with single SES
ersus BMS was maintained in the comparison of overlap
tent-treated patients. Thus, polymer-based elution of
irolimus appears to be effective in reducing the enhanced
egree of neointimal proliferation and late lumen loss
bserved in overlapped stents. Of note, after multivariable
egression analysis with adjustments for total stent length
eployed and target lesion length, stent overlap remained a
redictor of in-stent restenosis for BMS but not SES.
tent thrombosis. Although both stent length (29) and
tent overlap (30) have been incriminated as being associ-
ted with an increased incidence of drug-eluting stent
hrombosis, no such relationship was identified in the
urrent study despite complete follow-up to one year in all
ubjects. Combination oral antiplatelet therapy with aspirin
nd clopidogrel was mandated by study protocol for only
hree months for the trials included in this analysis. Al-
hough concerns that stent overlap might increase the
ikelihood of subsequent stent strut malapposition, and thus
he propensity for thrombosis, late follow-up (to 1,080 days)
rom the cumulative experience in four randomized com-
arative trials of SES versus BMS demonstrates no evidence
or an increase in stent thrombosis (M. Leon, personal
ommunication, May 2005). Similarly, no evidence for an
ncrease in localized aneurysm formation at the overlap
egment was observed by quantitative angiography in the
urrent study or by intravascular ultrasound in previous
eports (31,32).
ACE related to stent overlap. Although stent overlap
as associated with an increase in total MACE to both 30
ays and 1 year for BMS-treated patients, no increase in
ACE was observed in patients who received overlapping
ES. The major differences between patients treated with
verlapping stents by stent type were in the frequency
ccurrence of target lesion and target vessel revasculariza-
ion, as well as target vessel failure (increased in BMS- vs.
ES-treated cohorts).
tudy limitations. The major limitation of the present
nalysis, which compares patients treated with overlapping
tents, is that the decision to deploy stents in an overlapping
ashion was not randomly assigned. However, the factors
rompting overlapping stent deployment were not predict-
ble in the majority of cases, and the portion of patients who
equired stent overlap was similar between SES- and BMS-
reated patients among those enrolled into randomized
omparative trials. Furthermore, the present study repre-
ents the largest experience to date for patients with over-
apping coronary stents that includes complete angiographic
nd late clinical follow-up. In addition, although data fromoth randomized and non-randomized trials were pooled
or this report, separate detailed analyses demonstrated all
linical and angiographic end points to be similar between
he three randomized trials and all five trials (Appendix). Of
ote, patients enrolled into all five trials had similar baseline
linical and angiographic characteristics.
onclusions. This analysis of patients with overlapping
ES or BMS platforms demonstrates that stent overlap is a
timulus for neointimal proliferation and late lumen loss
ith subsequent restenosis regardless of stent type. Stent-
ased polymer elution of sirolimus is effective in suppressing
eointimal hyperplasia and provides a similar degree of reste-
osis benefit when compared with BMS in both overlapped
nd single-stent–treated patient cohorts. Sirolimus-eluting
tent overlap is not associated with an increased incidence of
yocardial infarction or MACE in late follow-up when
ompared with either single SES-treated patients or with
atients treated with single or overlapped BMS. Thus, the
trategy of SES overlap, when required, is both safe and
fficacious in reducing restenosis in comparison with a BMS
rosthesis. Careful attention should be paid to achieve
ptimal stent deployment in those cases where stent overlap
s required.
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